Codexis, Inc. (CDXS) |
| 1.07 -0.05 (-4.46%) 02-26 16:00 |
| Open: | 1.135 |
| High: | 1.135 |
| Low: | 1.055 |
| Volume: | 1,193,549 |
| Market Cap: | 97(M) |
| PE Ratio: | -1.47 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 1.89 |
| Resistance 1: | 1.57 |
| Pivot price: | 1.19 |
| Support 1: | 1.05 |
| Support 2: | 0.87 |
| 52w High: | 3.87 |
| 52w Low: | 1.05 |
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
| EPS | -0.730 |
| Book Value | 0.430 |
| PEG Ratio | 0.00 |
| Gross Profit | -0.118 |
| Profit Margin (%) | -120.82 |
| Operating Margin (%) | -220.31 |
| Return on Assets (ttm) | -27.4 |
| Return on Equity (ttm) | -114.3 |
Thu, 12 Feb 2026
Positive Sentiment Still Eludes Codexis, Inc. (NASDAQ:CDXS) Following 29% Share Price Slump - simplywall.st
Tue, 10 Feb 2026
Codexis (CDXS) Achieves ISO 9001:2015 Certification - GuruFocus
Tue, 10 Feb 2026
Codexis Inc. Achieves ISO 9001:2015 Certification for Quality Management Excellence - Quiver Quantitative
Tue, 10 Feb 2026
What Codexis’ new ISO 9001 status means for enzyme buyers - Stock Titan
Sat, 07 Feb 2026
Analysts Expect Breakeven For Codexis, Inc. (NASDAQ:CDXS) Before Long - Yahoo Finance
Mon, 15 Dec 2025
Opaleye management sells Codexis (CDXS) shares for $1.87 million - Investing.com
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |